9,191 Shares in MiMedx Group, Inc. (NASDAQ:MDXG) Acquired by AlphaQuest LLC

AlphaQuest LLC acquired a new stake in MiMedx Group, Inc. (NASDAQ:MDXG) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 9,191 shares of the company’s stock, valued at approximately $88,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MDXG. Principal Financial Group Inc. boosted its position in shares of MiMedx Group by 6.3% in the third quarter. Principal Financial Group Inc. now owns 55,495 shares of the company’s stock valued at $328,000 after acquiring an additional 3,292 shares during the period. Victory Capital Management Inc. raised its stake in MiMedx Group by 2.8% in the 3rd quarter. Victory Capital Management Inc. now owns 142,350 shares of the company’s stock worth $841,000 after purchasing an additional 3,901 shares in the last quarter. Royce & Associates LP boosted its holdings in MiMedx Group by 5.3% in the 3rd quarter. Royce & Associates LP now owns 972,853 shares of the company’s stock valued at $5,750,000 after purchasing an additional 48,539 shares during the period. Intech Investment Management LLC acquired a new position in shares of MiMedx Group during the 3rd quarter worth approximately $119,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of MiMedx Group by 6.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company’s stock worth $8,483,000 after purchasing an additional 92,726 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a research note on Thursday, February 27th.

Insider Buying and Selling at MiMedx Group

In other news, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the transaction, the insider now owns 310,836 shares of the company’s stock, valued at approximately $2,452,496.04. This represents a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO William Frank Iv Hulse sold 81,446 shares of MiMedx Group stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $7.80, for a total transaction of $635,278.80. Following the sale, the chief accounting officer now directly owns 494,774 shares in the company, valued at $3,859,237.20. This trade represents a 14.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 142,259 shares of company stock valued at $1,116,170. 1.30% of the stock is currently owned by corporate insiders.

MiMedx Group Trading Down 1.5 %

MDXG opened at $7.92 on Wednesday. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of 14.40 and a beta of 1.97. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14. The company has a 50-day simple moving average of $8.42 and a 200 day simple moving average of $7.84.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.07. The company had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. Analysts predict that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.